Scarica l'app Stockscreener
9.60
1.69%
0.16
Pre-mercato:
9.45
-0.15
-1.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Relay Ther - GuruFocus
Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies - Traders Union
Aug Summary: Will Relay Therapeutics Inc benefit from government policy2026 Macro Impact & Fast Moving Trade Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook for RLAY Q1 Earnings - MarketBeat
RLAY: HC Wainwright & Co. Raises Price Target to $19.00, Maintai - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target on trial data - Investing.com
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Did Phase 1/2 ReDiscover Data Just Reframe Relay Therapeutics' (RLAY) Late-Stage Breast Cancer Strategy? - Sahm
Aug Update: What is the earnings history of Relay Therapeutics IncTrade Analysis Report & Target Return Focused Picks - baoquankhu1.vn
Relay Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - AOL.com
Raymond James reiterates Strong Buy on Relay Therapeutics stock By Investing.com - Investing.com Canada
Profit Review: Can Relay Therapeutics Inc sustain its profitability2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial - Sahm
Relay Therapeutics Price Target Raised to $17.00 - National Today
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Wells Fargo Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Oppenheimer reiterates Relay Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Relay Therapeutics (RLAY) Unveils Promising Phase 1/2 Trial Resu - GuruFocus
Relay Therapeutics Reports Promising Phase 3 Data for Zovegalisib + Fulvestrant in PI3Kα-Mutated HR+/HER2- Metastatic Breast Cancer at ESMO TAT 2026 12 - Minichart
Relay Therapeutics Sees Unusually Large Options Volume - National Today
Relay Therapeutics Sees Unusually Large Options Volume (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free SurvivalWhat Does This Means For Pretreated Breast Cancer Patients? - Benzinga
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - Bitget
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data - TipRanks
Relay Therapeutics Announces Data from Zovegalisib Plus Fulvestrant At the Phase 3 Dose of 400Mg BID Fed - marketscreener.com
Relay Therapeutics reports 11.1-month median PFS for zovegalisib 400mg BID fed in PI3Kα-mutant MBC - TradingView
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Relay Therapeutics moves ReDiscover regimen with zovegalisib and fulvestrant to Phase 3 trial - Traders Union
Experimental Relay cancer drug combo shows 11.1-month progression-free survival - Stock Titan
Commodore Capital Boosts Stake in Relay Therapeutics - National Today
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Guggenheim Sticks to Its Buy Rating for Relay Therapeutics (RLAY) - The Globe and Mail
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY) - The Globe and Mail
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (RLAY) CFO sells 17,717 shares under 10b5-1 plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) sets federal courts for securities claims - Stock Titan
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):